GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sera Prognostics Inc (NAS:SERA) » Definitions » EV-to-FCF

Sera Prognostics (Sera Prognostics) EV-to-FCF : -11.00 (As of May. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sera Prognostics's Enterprise Value is $300.40 Mil. Sera Prognostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-27.32 Mil. Therefore, Sera Prognostics's EV-to-FCF for today is -11.00.

The historical rank and industry rank for Sera Prognostics's EV-to-FCF or its related term are showing as below:

SERA' s EV-to-FCF Range Over the Past 10 Years
Min: -14.04   Med: -1.06   Max: 1.92
Current: -11

During the past 5 years, the highest EV-to-FCF of Sera Prognostics was 1.92. The lowest was -14.04. And the median was -1.06.

SERA's EV-to-FCF is ranked worse than
100% of 104 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.875 vs SERA: -11.00

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-04), Sera Prognostics's stock price is $10.85. Sera Prognostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.160. Therefore, Sera Prognostics's PE Ratio for today is At Loss.


Sera Prognostics EV-to-FCF Historical Data

The historical data trend for Sera Prognostics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sera Prognostics EV-to-FCF Chart

Sera Prognostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -3.23 1.15 -5.21

Sera Prognostics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 -1.65 -1.40 -0.51 -5.21

Competitive Comparison of Sera Prognostics's EV-to-FCF

For the Diagnostics & Research subindustry, Sera Prognostics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sera Prognostics's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sera Prognostics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sera Prognostics's EV-to-FCF falls into.



Sera Prognostics EV-to-FCF Calculation

Sera Prognostics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=300.403/-27.316
=-11.00

Sera Prognostics's current Enterprise Value is $300.40 Mil.
Sera Prognostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sera Prognostics  (NAS:SERA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sera Prognostics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=10.85/-1.160
=At Loss

Sera Prognostics's share price for today is $10.85.
Sera Prognostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.160.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sera Prognostics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sera Prognostics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sera Prognostics (Sera Prognostics) Business Description

Traded in Other Exchanges
N/A
Address
2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, and other pregnancy complications.
Executives
John J. Boniface officer: Chief Scientific Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Benjamin Jackson officer: General Counsel 320 WAKARA WAY, SALT LAKE CITY UT 84108
Austin Aerts officer: Chief Financial Officer 2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Robert Gardner Harrison officer: Chief Information Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley officer: Chief Medical Officer C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence director C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Zhenya Lindgardt director C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
Paul Kearney officer: Chief Data Officer 2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Kim P. Kamdar director C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Blue Ox Healthcare Partners, Llc 10 percent owner 239 DAWSON ROAD, HILLSIDE NY 12529
Nichole L. Martin officer: VP OF Q/R & HIPPA PRIV. OFF C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Marcus Dean Wilson director C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Joshua Phillips director C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Nadia Altomare officer: Chief Commercial Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109